Lung Cancer

atypical carcinoid lung tumor survival rate :: Article Creator

large cell neuroendocrine :: Article Creator Refractory Neuroendocrine Tumor—response To Liposomal Doxorubicin And Capecitabine Background. A 61-year-old patient with no relevant medical or family history presented with a 2 month history of refractory dry cough that led to the diagnosis of typical carcinoid tumor of the lung metastatic to the mediastinal lymph nodes and liver. She initially received a long-acting somatostatin analog (octreotide) and chemotherapy with cisplatin and etoposide, which was ineffective. Investigations. Physical examination, laboratory test, chromogranin A test, CT scan, 111In-diethylenetriaminepentaacetic acid (DTPA)-octreotide scan, 18F-FDG-PET scan, fine-needle and tissue core liver biopsies. Diagnosis. Pulmonary spindle-cell carcinoid tumor with metastases to mediastinal lymph nodes and liver. Management. Systemic treatment with oral capecitabine (1,500 mg/m2 daily from day 1 to day 21) and intravenous liposomal

stage 4 small cell :: Article Creator Positive Trials Continue To Shape The SCLC Treatment Landscape In an interview with Targeted Oncology, Ariel Lopez-Chavez, MD, discussed recent developments in the small cell lung cancer space. Recent advancements in small cell lung cancer (SCLC) treatments have introduced transformative therapies and trial results, according to Ariel Lopez-Chavez MD. Notably, the FDA granted accelerated approved to tarlatamab-dlle (Imdelltra), a bispecific T-cell engager (BiTE) for the treatment of SCLC that has progressed on or after platinum-based chemotherapy, in May 2024, offering a new option for patients with second-line SCLC.1 This approval was based on findings from the phase 2 DeLLphi-301 study (NCT05060016).2 Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping treatment approaches. In extensive-stage SCLC, immune checkpoint inhibitors atez

small cell squamous carcinoma :: Article Creator Lung Cancer – Looking Beyond Smoke And Mirrors Patients with lung cancer who have never smoked are usually diagnosed too late for curative treatment. Pam Dalrymple, advanced clinical nurse specialist in lung cancer at NHS Greater Glasgow and Clyde, discusses how practice nurses can support these patients It is well known that lung cancer is primarily associated with smoking. Almost three-quarters of all lung cancers are caused by tobacco smoke exposure, and the outlook is generally quite poor. According to Cancer Research UK, just 10% of patients survive for 10 years or more. That makes it all the more devastating that 79% of cases are preventable.1 Screening is a significant step forward in diagnosing people with lung cancer sooner, and hopefully saving more lives. A lung cancer screening programme was launched last year in England and a similar pilot scheme is under way in parts of Scotland – both

merkel cell carcinoma symptoms :: Article Creator Dear Doctor: I'm Taking An Aromatase Inhibitor For Cancer And It's Ruining My Quality Of Life DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip. I have been on an aromatase inhibitor for the past eight months and have side effects that keep me from having a good quality of life. I am supposed to be on it for five years, but I do not want to live the rest of my life like this. I cannot find any statistics for someone my age. I would appreciate any advice you have for me. -- S.M. ANSWER: There's no statistics on anyone like you because you are unique. I doubt anyone in the world has had your experience. So, in absence of data, we physicians have to use our clinical judgement. The real issue here isn't the ovarian cancer, th

triple positive breast cancer prognosis :: Article Creator What Is Triple Positive Breast Cancer? 'The Office' Star Jenna Fischer Opens Up About Diagnosis, Hair Loss Jenna Fischer is opening up about her cancer diagnosis and how she's doing these days. In an Instagram post earlier this month, The Office alum shared that she has quietly been in treatment for cancer. "I never thought I'd be making an announcement like this, but here we are," she wrote in the caption of a length post, which started with a photo of herself and ended with the 50-year-old celebrating "ringing the bell" with her family. (Typically, cancer patients ring a bell after completing treatment.) A few weeks later on October 21, Jenna opened up to Today about her journey to diagnosis, including how her initial mammogram led to a series of other tests. Here's what Jenna shared about her diagnosis, plus how she's doing now. What c

follicular lymphoma stage 4 :: Article Creator How Lunsumio Works To Treat Follicular Lymphoma Lunsumio is a type of cancer treatment called immunotherapy. Immunotherapy works by using the body's immune system to fight cancer cells. Lunsumio is designed to help the immune system fight a type of lymphoma called follicular lymphoma (FL) that has either come back after previous therapy (relapsed) or did not go away after previous therapy (refractory). Lunsumio is a type of immunotherapy called a bispecific antibody.  Lunsumio is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on lymphoma cells and to CD3 proteins on T cells, a type of immune cell that can kill cancer cells. When Lunsumio attaches to CD20 and CD3, this activates the T cells, makes them multiply, and helps them release chemicals that destroy the lymphoma cells with CD20 on them. Lun